Bric health systems and big pharma: A challenge for health policy and management

Victor Rodwin, Guilhem Fabre, Rafael F. Ayoub

Research output: Contribution to journalEditorial

Abstract

BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases of how governments manage the tensions posed by rising public expectations and limited resources to satisfy them. Understanding these tensions represents an emerging area of research and an important challenge for all those who work in the field of health policy and management (HPAM).

Original languageEnglish (US)
Pages (from-to)201-206
Number of pages6
JournalInternational Journal of Health Policy and Management
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Health Policy
Delivery of Health Care
Health
Prescription Drugs
Russia
Health Expenditures
Social Class
Brazil
India
China
Chronic Disease
Growth
Research
Pharmaceutical Preparations
Population

Keywords

  • Brazil
  • BRIC
  • China
  • Health systems
  • Healthcare
  • India
  • Pharma
  • Pharmerging
  • Population health
  • Russia

ASJC Scopus subject areas

  • Health Policy

Cite this

Bric health systems and big pharma : A challenge for health policy and management. / Rodwin, Victor; Fabre, Guilhem; Ayoub, Rafael F.

In: International Journal of Health Policy and Management, Vol. 7, No. 3, 01.03.2018, p. 201-206.

Research output: Contribution to journalEditorial

@article{1838f2a5608f4dc6830871494ed724b7,
title = "Bric health systems and big pharma: A challenge for health policy and management",
abstract = "BRIC nations – Brazil, Russia, India, and China – represent 40{\%} of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases of how governments manage the tensions posed by rising public expectations and limited resources to satisfy them. Understanding these tensions represents an emerging area of research and an important challenge for all those who work in the field of health policy and management (HPAM).",
keywords = "Brazil, BRIC, China, Health systems, Healthcare, India, Pharma, Pharmerging, Population health, Russia",
author = "Victor Rodwin and Guilhem Fabre and Ayoub, {Rafael F.}",
year = "2018",
month = "3",
day = "1",
doi = "10.15171/ijhpm.2017.145",
language = "English (US)",
volume = "7",
pages = "201--206",
journal = "International Journal of Health Policy and Management",
issn = "2322-5939",
publisher = "Kerman University of Medical Science",
number = "3",

}

TY - JOUR

T1 - Bric health systems and big pharma

T2 - A challenge for health policy and management

AU - Rodwin, Victor

AU - Fabre, Guilhem

AU - Ayoub, Rafael F.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases of how governments manage the tensions posed by rising public expectations and limited resources to satisfy them. Understanding these tensions represents an emerging area of research and an important challenge for all those who work in the field of health policy and management (HPAM).

AB - BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases of how governments manage the tensions posed by rising public expectations and limited resources to satisfy them. Understanding these tensions represents an emerging area of research and an important challenge for all those who work in the field of health policy and management (HPAM).

KW - Brazil

KW - BRIC

KW - China

KW - Health systems

KW - Healthcare

KW - India

KW - Pharma

KW - Pharmerging

KW - Population health

KW - Russia

UR - http://www.scopus.com/inward/record.url?scp=85043595937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043595937&partnerID=8YFLogxK

U2 - 10.15171/ijhpm.2017.145

DO - 10.15171/ijhpm.2017.145

M3 - Editorial

C2 - 29524948

AN - SCOPUS:85043595937

VL - 7

SP - 201

EP - 206

JO - International Journal of Health Policy and Management

JF - International Journal of Health Policy and Management

SN - 2322-5939

IS - 3

ER -